Diabetes and Endocrinology

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

Why choose INVOKANA?

Find Out More Prescribing Information (GB) Prescribing Information (NI)

CREDENCE

Clinical evidence for using Invokana^® (canagliflozin) in your type 2 diabetic patients with diabetic kidney disease

Find out more

CANVAS

Clinical evidence for using Invokana^® (canagliflozin) in your type 2 diabetes patients at high risk of adverse cardiovascular events

Find Out More

Support for your patients with type 2 diabetes

Find Out More

PP-IN-UK-0240 July 2023